Kaftrio Opens to All CF Patients, 12 and Up, in EU With F508del Mutation

Kaftrio Opens to All CF Patients, 12 and Up, in EU With F508del Mutation

293173

Kaftrio Opens to All CF Patients, 12 and Up, in EU With F508del Mutation

The European Commission (EC) agreed to expand use of Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include cystic fibrosis (CF) patients 12 and older who have at least one copy of the CFTR gene with an F508del mutation. The EC approved this combination therapy last year to treat people 12 and older whose CF is due to either two F508del mutations or one F508del mutation and one minimal function mutation in the CFTR gene. But that approval did…

You must be logged in to read/download the full post.